|
| Status |
Public on Feb 23, 2024 |
| Title |
PKP2 Gene Therapy Improves Heart Function and Reduces Mortality in a Pkp2-deficient Mouse Model of Arrhythmogenic Right Ventricular Cardiomyopathy |
| Organisms |
Homo sapiens; Mus musculus |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
This SuperSeries is composed of the SubSeries listed below.
|
| |
|
| Overall design |
Refer to individual Series
|
| Web link |
https://doi.org/10.1038/s43856-024-00450-w
|
| |
|
| Citation(s) |
38499690 |
| |
| Submission date |
Jan 14, 2024 |
| Last update date |
May 24, 2024 |
| Contact name |
Farshad Farshidfar |
| E-mail(s) |
ffarshidfar@tenayathera.com
|
| Organization name |
Tenaya Therapeutics Inc.
|
| Street address |
171 Oyster Point Blvd Ste 500
|
| City |
South San Francisco |
| State/province |
CA |
| ZIP/Postal code |
94080 |
| Country |
USA |
| |
|
| Platforms (2) |
| GPL24247 |
Illumina NovaSeq 6000 (Mus musculus) |
| GPL24676 |
Illumina NovaSeq 6000 (Homo sapiens) |
|
| Samples (112)
|
|
| This SuperSeries is composed of the following SubSeries: |
| GSE253223 |
TNYA0016: Time-dependent transcriptional effects of PKP2 mRNA knockdown in wild-type human iPSC-CMs |
| GSE253224 |
TNYA0042: TN-401 dose-dependent efficacy study at about 10 weeks in Pkp2-cKO ARVC mouse model |
| GSE253225 |
TNYA0044: AAV9:mPkp2 preventive vs therapeutic modes of treatment at 51 weeks in Pkp2-cKO ARVC mouse model |
|
| Relations |
| BioProject |
PRJNA1064591 |
Less...
More...